Precision oncology in urogenital and gynecological tumors (Ongoing)

The series on “Precision oncology in urogenital and gynecological tumors” is edited by Drs Elie Rassy (Gustave Roussy Institut, France), Nicholas Pavlidis (University of Ioannina, Greece), Stergios Boussios (Medway NHS Foundation Trust, UK), and Joseph Kattan (Saint Joseph University, Lebanon).

Read More>>

Precision Cancer Medicine (PCM) is now a member of Committee on Publication Ethics (COPE)

Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Precision Cancer Medicine (PCM) is among the list of COPE membership.

Read More>>

ALK and ROS-1 NSCLC Patients Treatment Approach Based on Genomic Profile by Liquid Biopsy

ALK and ROS-1 tyrosine kinase inhibitors (TKIs) have become the new standard of care in the first-line treatment of advanced ALK and ROS-1 positive NSCLC patients. As there are several TKIs, upon progression, the optimal sequential ALK and ROS-1 TKI strategy at progression is relevant, and this may have an impact on patients' outcome. Mechanisms of acquired resistance knowledge will be also relevant to develop new personalized treatment strategies to overcome in the near future.

Read More>>

How to Detect and Treat NSCLC Patients with Oncogenic Fusions (Ongoing)

The series on “How to Detect and Treat NSCLC Patients with Oncogenic Fusions” is edited by Drs Fabrizio Tabbò (University of Turin, Italy), Umberto Malapelle (University of Naples Federico II, Italy), Maria Lucia Reale (University of Turin, Italy), Angela Listì (University of Turin, Italy).

Read More>>

Eastern and Western Perspectives on Precision Cancer Medicine

The series on “Eastern and Western Perspectives on Precision Cancer Medicine” was edited by Drs Zhi-Ming Shao and Xiao-Mao Guo, Fudan University Shanghai Cancer Center, Shanghai, China.

Read More>>

PCM Annual Report 2022

We are pleased to present the 2022 Annual Report of Precision Cancer Medicine (PCM). PCM has formed an internationalized editorial board of 211 members from 18 countries, and published 40 articles of authors from 14 countries. Besides, it has attracted internationally diverse readers from 152 countries/regions with stably increasing website pageviews up to 91,916 in 2022. The journal also features special series exploring trending topics, as well as the Chinese Edition that enhances the links between Chinese scientists and the international medical community.

Read More>>

Quality Assurance in Radiotherapy (Ongoing)

The series on “Quality Assurance in Radiotherapy” is edited by Drs Paul Van Houtte and Dirk Van Gestel (Institut Jules Bordet, Belgium). This series is to provide a comprehensive review and further discussion on quality assurance in radiotherapy, and include empirical experience and valuable opinions from recognized experts in this field from prestigious institutions of different countries.

Read More>>

Reviewer of the Month (2022)

Over the year, many PCM reviewers have made outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

Read More>>

Interviews with Outstanding Authors (2022)

In 2022, many PCM authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors who have been making immense efforts in their research fields, with a brief interview of their unique perspective and insightful view as authors.

Read More>>

Uncommon Mutations in Non-Small Cell Lung Cancer (Ongoing)

The series on “Uncommon Mutations in Non-Small Cell Lung Cancer” is edited by Dr. Marco Russano, Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.

Read More>>

Evidence and Controversies in the treatment of metastatic NSCLC

The series on “Evidence and Controversies in the treatment of metastatic NSCLC” is edited by Dr. Grace K. Dy, MD, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. This series has included a collection of debate-style brief editorials, featuring back-to-back pro/con position from different clinical experts in the field.

Read More>>

Non-Small Cell Lung Cancer (NSCLC)

The series “Non-Small Cell Lung Cancer (NSCLC)” was edited by Dr. Alfredo Addeo, Oncology Department, University Hospital Geneva, Geneva, Switzerland and Dr. Giuseppe Banna, Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

Read More>>

Lung Cancer In Women: From Epidemiology To Therapy (Ongoing)

This series on “Lung Cancer In Women: From Epidemiology To Therapy” is edited by Dr. Editta Baldini, from Department of Medical Oncology, San Luca Hospital, Lucca, Italy and Dr. Franca Melfi, from Robotic Multispecialty Center for Surgery, University Hospital of Pisa, Pisa, Italy.

Read More>>

Management of Triple Negative Breast Cancer (Ongoing)

This series on “Management of Triple Negative Breast Cancer” is edited by Dr. Jacques Raphael, MD, Department of Oncology, Western University, London, ON, Canada. This series will explore different options, approaches and techniques such as chemotherapy, immunotherapy, adjuvant and neoadjuvant chemotherapy, as well as radiation therapy and biomarkers etc., so as to improve the treatments for triple negative breast cancer.

Read More>>

Precision Oncology Tumor Board

Guest Editor: Balazs Halmos, MD
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

The Precision Oncology Tumor Board is to provide a global forum for dialogue and education for discussion about the optimal use of biomarker testing in a vast number of emerging clinical settings. An article for this column could be a Case-Based Review, providing a case with educational values and relevant review of the literature and highlighting the level of evidence supporting key decisions. The format of this category is recommended as follows: Introduction, Case Presentation, Tumor Management, Case-related Literature Review and Conclusion. Specific guidelines of this series could be found in the Author Instructions.

Read More>>